PRA Health Sciences PE Ratio 2013-2018 | PRAH

Current and historical p/e ratio for PRA Health Sciences (PRAH) from 2013 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. PRA Health Sciences PE ratio as of November 16, 2018 is 26.68.
PRA Health Sciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-16 100.60 100.60
2018-09-30 110.19 $1.00 110.19
2018-06-30 93.36 $1.71 54.60
2018-03-31 82.96 $1.52 54.58
2017-12-31 91.07 $1.32 68.99
2017-09-30 76.17 $1.79 42.55
2017-06-30 75.01 $1.55 48.39
2017-03-31 65.23 $1.70 38.37
2016-12-31 55.12 $1.04 53.00
2016-09-30 56.51 $1.27 44.50
2016-06-30 41.76 $1.15 36.31
2016-03-31 42.76 $0.75 57.01
2015-12-31 45.27 $1.29 35.09
2015-09-30 38.83 $0.39 99.56
Sector Industry Market Cap Revenue
Medical Medical Services $6.536B $2.259B
PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.055B 11.38
ICON (ICLR) Ireland $7.186B 22.52
Charles River Laboratories (CRL) United States $6.295B 22.07
HealthEquity (HQY) United States $5.293B 110.78
Premier (PINC) United States $5.276B 17.90
INC Research Holdings (SYNH) United States $5.161B 20.83
Teladoc (TDOC) United States $4.142B 0.00
NovoCure (NVCR) Jersey $2.933B 0.00
AMN Healthcare Services Inc (AMN) United States $2.890B 19.83
BioTelemetry (BEAT) United States $2.126B 37.55
Medpace Holdings (MEDP) United States $1.974B 24.42
Healthways (TVTY) United States $1.472B 18.10
Intrexon (XON) United States $1.393B 0.00
CareDx (CDNA) United States $1.165B 0.00
IKang Healthcare (KANG) China $1.161B 57.66
Natera (NTRA) United States $1.037B 0.00
China Cord Blood (CO) China $0.794B 21.06
Apollo Medical Holdings (AMEH) United States $0.742B 0.00
Surgery Partners (SGRY) United States $0.641B 0.00
Establishment Labs Holdings (ESTA) $0.536B 0.00
Civitas Solutions (CIVI) United States $0.525B 10.34
OncoCyte (OCX) United States $0.069B 0.00
Interpace Diagnostics (IDXG) United States $0.034B 0.00
Cancer Genetics (CGIX) United States $0.014B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00